Related Experiment Video
Updated: Mar 9, 2026

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Early elemental diet supplementation during chemotherapy improves treatment response and survival in advanced
Shinya Uemura1, Takuji Iwashita2, Takuya Koizumi1
1First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
Background & Aim:
Patients with advanced pancreatic cancer often develop nutritional disorders such as malnutrition, sarcopenia, and cachexia early in the disease course. Although various interventions have been explored, no standard approach exists. This study was conducted to evaluate the efficacy of an elemental diet (ED) as nutritional support during chemotherapy.
Methods:
In this randomized trial, patients were assigned to an ED intervention (EI) group or a normal diet (ND) group. The EI group consumed ≥1 packet/day of ED for ≥2 months. The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS) and nutritional parameters.
Results:
Sixty patients were randomized (EI: n = 30, ND: n = 30), with three withdrawals from EI. Baseline characteristics were similar. Median ED duration was 5.6 months. Over two months, BMI declined less in EI (-0.3 kg/m2) than in ND (-0.6 kg/m2, p = 0.044). Serum protein markers (TP, ALB, Tf, TTR) decreased significantly in ND. Handgrip strength was better preserved in EI (p = 0.010), although skeletal muscle index showed no difference (p = 0.480). First-line chemotherapy disease control rate (96.3 % vs 73.3 %, p = 0.027) and overall response rate (44.4 % vs 10.3 %, p = 0.006) were significantly higher in EI. Grade ≥3 adverse events were similar. Median PFS was 9.5 vs 6.4 months (p = 0.068), and OS was significantly longer in EI (21.4 vs 12.8 months; HR 0.55, 95 % CI 0.31-0.98; p = 0.038).
Conclusion:
Early ED supplementation during chemotherapy was associated with preserved nutritional status, improved treatment response, and prolonged overall survival in patients with advanced pancreatic cancer.
Clinical Trial Registration:
UMIN000028659 (https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032805).
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chronic Kidney Disease III: Interprofessional Care
Targeted Cancer Therapies
There are several types of targeted therapies against...

